论文部分内容阅读
目的 :探讨结直肠癌患者血清血管内皮生长因子 (vascularendothelialgrowthfactor ,VEGF)水平变化的临床意义。方法 :采用双抗夹心ELISA法检测 45例结直肠癌患者血清VEGF水平 ,并与正常人比较。结果 :结直肠癌患者血清VEGF水平 [( 199 47± 15 6 69)pg/mL]显著高于正常对照组 [( 5 1 2 3± 2 2 66)pg/mL] ,P =0 0 0 0 ;有血管侵犯 [( 2 5 1 63±170 19)pg/mL ]、淋巴结转移 [( 2 66 3 9±162 49)pg/mL]和肝脏转移 [( 3 14 48± 2 19 89)pg/mL]的结直肠癌患者血清VEGF水平明显高于无血管侵犯 [( 12 1 2 3± 91 91)pg/mL]、无淋巴结转移 [( 189 2 6± 47 14 )pg/mL]和无肝脏转移 [( 15 7 65± 10 1 86)pg/mL]的患者 ,分别P =0 0 0 5 ,P =0 0 0 0 ,P =0 0 0 2 ;Duke’sC、D期的结直肠癌患者血清VEGF水平 [( 2 60 74±174 72 )pg/mL]显著高于Duke’sA、B期患者[( 115 63± 69 10 )pg/mL] ,P =0 0 0 1;结直肠肿瘤≥ 5cm的患者血清VEGF水平 [( 2 44 74±171 18)pg/mL]明显高于肿瘤 <5cm的患者[( 12 4 92± 92 62 )pg/mL] ,P =0 0 0 4。血清VEGF水平与患者性别、年龄和组织病理学类型无明显关系。结论 :血清VEGF有可能成为一个新的肿瘤标志物而用于结直肠癌诊断、病情进展的动态监测及预后判断的
Objective: To investigate the clinical significance of the changes of serum vascular endothelial growth factor (VEGF) in patients with colorectal cancer. Methods: Serum VEGF levels in 45 patients with colorectal cancer were detected by double-antibody sandwich ELISA and compared with normal subjects. Results: Serum VEGF level in patients with colorectal cancer was significantly higher than that in the control group [(199 47 ± 15 6 69) pg / mL] (P 5 1 2 3 ± 2 2 66 pg / mL) ; Vascular invasion [(2 5 1 63 ± 170 19) pg / mL], lymph node metastasis [(2 663 9 ± 162 49) pg / mL] and liver metastasis [(3 14 48 ± 2 19 89) pg / mL] in patients with colorectal cancer were significantly higher than those without vascular invasion [(12 1 ± 3 ± 91 91) pg / mL], no lymph node metastasis [(189 2 6 ± 47 14) pg / mL] Patients with metastasis [(15 7 65 ± 10 1 86) pg / mL] had colorectal cancer with Duke’s C and D stages, P = 0 0 05, P 0 0 0 0, P 0 0 0 2, respectively Serum levels of VEGF in patients [(2 60 74 ± 174 72) pg / mL] were significantly higher than those in Dukes’ s A and B [(115 63 ± 69 10) pg / mL], P 0 01; Serum levels of VEGF in patients ≥ 5 cm were significantly higher than those in patients <5 cm [(12 442 ± 92 62) pg / mL] [P (2 44 74 ± 171 18) pg / mL], P = 0.004. There was no significant correlation between serum VEGF level and patient’s sex, age and histopathological type. Conclusion: Serum VEGF may become a new tumor marker for the diagnosis of colorectal cancer, the dynamic monitoring of disease progression and prognosis